Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04699630 · ClinicalTrials.gov registry record · Phase 2
A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer
A Phase 2 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 121
- Enrollment target
NCT04699630 is a Phase 2 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 121 participants.
The verdict
NCT04699630, a Phase 2 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 121 participants
- Enrollment target
Study Summary
This study is to evaluate safety and efficacy of an antibody drug conjugate U3-1402 (patritumab deruxtecan) in patients with locally advanced or metastatic breast cancer (MBC).
Interventions
- DRUG U3-1402
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2021-05-03 |
| Est. Completion | 2025-04-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04699630
The ClinicalTrials.gov registry entry for NCT04699630 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which U3-1402 is the first listed.
NCT04699630 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04699630 about?
NCT04699630 is a clinical study titled "A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer". This study is to evaluate safety and efficacy of an antibody drug conjugate U3-1402 (patritumab deruxtecan) in patients with locally advanced or metastatic breast cancer (MBC).
What is the current status of trial NCT04699630?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 121 participants. The study started on 2021-05-03. Estimated completion is 2025-04-09.
What interventions are being tested in trial NCT04699630?
The interventions under investigation include: U3-1402 (DRUG).
Who is sponsoring clinical trial NCT04699630?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.